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A practical approach to the use of antithrombotic therapy
in our patients should be primarily based on an understand-
ing of: 1) the pathophysiologic mechanisms of thrombosis,
2) the natural history of thrombotic risk, 3) the basic and
clinical pharmacology of the different antithrombotic agents,
and 4) the results of the many retrospective and prospective
studies performed in recent years that have provided im-
portant information on the value of different antithrombotic
regimens in the various cardiovascular conditions.
The articles in this Symposium link basic concepts in
platelet activation, coagulation, thrombus formation and fi-
brinolysis with the prevention and management of throm-
boembolism of cardiac, arterial and venous origin. First,
thrombogenesis and the interacting roles of platelet acti-
vation and coagulation are discussed by Vermylen et al.
Full knowledge of the pharmacology of antithrombotic agents,
either singly or in combination, is important for the selection
of an appropriate intervention in each thrombotic situation.
The pharmacology of heparin and oral anticoagulants is
discussed by Wessler and Gitel, of platelet inhibitors by
Harker and Fuster and of thrombolytic agents by Verstraete
and Collen.
In the next four articles, Chesebro, Fuster and their col-
laborators review the current state of the art of anti-
thrombotic therapy for thromboembolism in cardiac dis-
eases. These include 1) valvular heart disease and prosthetic
heart valves; 2) aortocoronary vein bypass graft occlusion
and postangioplasty restenosis; 3) unstable angina, myo-
cardial infarction and sudden death; and 4) cardiac sources
of thromboembolism such as acute myocardial infarction,
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dilated cardiomyopathy, left ventricular aneurysm, nonval-
vular atrial fibrillation and infective endocarditis.
In the two subsequent articles, thromboembolism in cere-
brovascular and peripheral vascular disease is discussed,
respectively, by Sherman and Hart and Bounameaux et aI.,
with an emphasis on pathogenesis and treatment. An ex-
tensive discussion of venous thromboembolism follows. The
epidemiology and pathogenesis, clinical features and di-
agnosis of venous thrombosis and pulmonary embolism are
detailed by Hirsh et aI., venous thrombosis in particular
organs is described by Kienast et al. and the preventive and
therapeutic approaches to venous thrombosis and pulmonary
embolism are discussed by Kakkar and Adams. The path-
ogenesis and treatment of disseminated intravascular co-
agulation are approached by Fruchtman and Aledort in the
final article.
Overall, this Symposium is intended to summarize a pru-
dent clinical approach to the treatment of thromboembolism
today, in 1986, based on a knowledge of the underlying
pathogenesis, the pharmacology of the antithrombotic agents,
the risk of thrombosis and bleeding and the results of clinical
trials where they exist. Today, and most important for the
future, the management of thrombosis links the clinician
with the clinical and basic investigator. The investigator
must provide the clinician with a fundamental understanding
of the mechanisms of thrombosis and the pharmacology of
antithrombotic agents. The investigator needs leads from
the clinician as to which clinical and biologic problems need
to be addressed. The two must work together to complete
clinical trials that fully evaluate the risks and benefits of
antithrombotic therapy in a practical setting.
Finally, we express our gratitude to all of the authors
from the United States and abroad for taking time to sum-
marize their authoritative views in this issue of the Journal
of the American College of Cardiology. Also, we would
like to thank our colleagues Philip Adams, MRCP and Marc
Cohen, MD for their valuable contributions in the final
editing of the manuscripts.
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